Enables tropomyosin binding activity. Predicted to be involved in actin cytoskeleton organization; lens fiber cell development; and muscle contraction. Predicted to act upstream of or within adult locomotory behavior. Predicted to be located in cytoskeleton; membrane; and sarcomere. Predicted to be part of COP9 signalosome. Predicted to be active in striated muscle thin filament. Orthologous to human TMOD1 (tropomodulin 1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 2,3,7,8-Tetrachlorodibenzofuran; 2,4-dinitrotoluene.
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD1 mRNA
[oxaliplatin co-treated with Topotecan] results in decreased expression of TMOD1 mRNA and [Topotecan co-treated with oxaliplatin] results in decreased expression of TMOD1 mRNA
[Raloxifene Hydrochloride co-treated with ESR1 protein] results in increased expression of TMOD1 mRNA and [Raloxifene Hydrochloride co-treated with ESR2 protein] results in decreased expression of TMOD1 mRNA
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMOD1 mRNA
[Tamoxifen co-treated with ESR1 protein] results in increased expression of TMOD1 mRNA and [Tamoxifen co-treated with ESR2 protein] results in decreased expression of TMOD1 mRNA
[oxaliplatin co-treated with Topotecan] results in decreased expression of TMOD1 mRNA and [Topotecan co-treated with oxaliplatin] results in decreased expression of TMOD1 mRNA